<b><i>Background:</i></b> This study was conducted to investigate the association between genetic variants in one-carbon metabolism and survival outcomes of surgically resected non-small cell lung cancer (NSCLC). <b><i>Methods:</i></b> We genotyped 41 potentially functional variants of 19 key genes in the one-carbon metabolism pathway among 750 NSCLC patients who underwent curative surgery. The association between genetic variants and overall survival (OS)/disease-free survival (DFS) were analyzed. <b><i>Results:</i></b> Among the 41 single-nucleotide polymorphisms (SNPs) analyzed, 4 SNPs (<i>MTHFD1L</i> rs6919680T>G and rs3849794T>C, <i>MTR</i> rs2853523C>A, and <i>MTHFR</i> rs4846049G>T) were significantly associated with survival outcomes. <i>MTHFD1L</i> rs6919680T>G and <i>MTR</i> rs2853523C>A were significantly associated with better OS (adjusted hazard ratio [aHR] = 0.73, 95% confidence interval [CI] = 0.54–0.99, <i>p</i> = 0.04) and worse OS (aHR = 2.14, 95% CI = 1.13–4.07, <i>p</i> = 0.02), respectively. <i>MTHFD1L</i> rs3849794T>C and <i>MTHFR</i> rs4846049G>T were significantly associated with worse DFS (aHR = 1.41, 95% CI = 1.08–1.83, <i>p</i> = 0.01; and aHR = 1.97, 95% CI = 1.10–3.53, <i>p</i> = 0.02, respectively). When the patients were divided according to histology, the associations were significant only in squamous cell carcinoma (SCC), but not in adenocarcinoma (AC). In SCC, <i>MTHFD1L</i> rs6919680T>G and <i>MTR</i> rs2853523C>A were significantly associated with better OS (aHR = 0.64, 95% CI = 0.41–1.00, <i>p</i> = 0.05) and worse OS (aHR = 2.77, 95% CI = 1.11–6.91, <i>p</i> = 0.03), respectively, and <i>MTHFD1L</i> rs3849794T>C and <i>MTHFR</i> rs4846049G>T were significantly associated with worse DFS (aHR = 1.73, 95% CI = 1.17–2.56, <i>p</i> = 0.01; and aHR = 2.78, 95% CI = 1.12–6.88, <i>p</i> = 0.03, respectively). <b><i>Conclusions:</i></b> Our results suggest that the genetic variants in the one-carbon metabolism pathway could be used as biomarkers for predicting the clinical outcomes of patients with early-stage NSCLC.